Why is Akums Drugs falling/rising?

As of 17-Sep, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 472.25, which reflects a decrease of 3.9 points or 0.82%. The stock has underperformed its sector today by 0.86% and has seen a trend reversal after three consecutive days of gains. In terms of returns, the stock has shown a modest increase of 0.67% over the past week, but it has significantly underperformed over the longer term, with a year-to-date decline of 25.99% and a staggering 44.73% drop over the past year. Additionally, the stock's delivery volume has decreased by 43.49% compared to its five-day average, indicating falling investor participation. While the company has a low debt-to-equity ratio and an attractive valuation with a return on equity of 10.6%, the stock's poor long-term growth, flat quarterly results, and below-par performance in recent periods contribute to its current decline.
In the broader market context, the stock's short-term performance of +0.67% over the past week is notably lower than the benchmark Sensex, which has risen by 1.56% in the same timeframe. This underperformance is further highlighted by the stock's negative returns over the past year compared to the Sensex's modest decline of 0.46%. The company's net sales growth of only 6.10% annually and a significant drop in profit after tax in the latest quarter, alongside the highest interest expenses recorded, suggest ongoing challenges that may deter investors. Overall, the combination of weak financial performance, declining investor interest, and unfavorable comparisons to the broader market are contributing to the stock's downward movement.